Whole-genome sequencing enabling the detection of a colistin-resistant hypermutating Citrobacter werkmanii strain harbouring a novel metallo-β-lactamase VIM-48

Peter, Silke; Bezdan, Daniela; Oberhettinger, Philipp; Vogel, Wichard; Dörfel, Daniela; Dick, Julia; Marschal, Matthias; Liese, Jan; Weidenmaier, Christopher; Autenrieth, Ingo B.; Ossowski, Stephan; Willmann, Matthias

doi:10.1016/j.ijantimicag.2018.01.015

Cited by 12 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limited use of Colistin in the past offered some protection against the emergence of bacterial Colistin-resistance, now leading to the recent revival of this substance. With Colistin's comeback, development of Colistin-resistance in gram-negative strains has been described as a growing phenomenon [31][32][33][34][35][36]. The underlying mechanism of resistance [32] and its origin (induced or selected) in this case can only be speculated upon.…”

Section: High Colistin Plasma Levels Do Not Prevent Development Of Comentioning

confidence: 99%

Extensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks

et al. 2020

View full text Add to dashboard Cite

(1) Background: With the rise of multi-/pan-drug resistant (MDR/PDR) pathogens, the less utilized antibiotic Colistin has made a comeback. Colistin fell out of favor due to its small therapeutic range and high potential for toxicity. Today, it is used again as a last resort substance in treating MDR/PDR pathogens. Although new guidelines with detailed recommendations for Colistin dosing are available, finding the right dose in critically ill patients with renal failure remains difficult. Here, we evaluate the efficiency of the current guidelines’ recommendations by using high resolution therapeutic drug monitoring of Colistin. (2) Methods: We analyzed plasma levels of Colistin and its prodrug colisthimethate sodium (CMS) in 779 samples, drawn from eight PDR-infected ICU patients, using a HPLC-MS/MS approach. The impact of renal function on proper Colistin target levels was assessed. (3) Results: CMS levels did not correlate with Colistin levels. Over-/Underdosing occurred regardless of renal function and mode of renal replacement therapy. Colistin elimination half-time appeared to be longer than previously reported. (4) Conclusion: Following dose recommendations from the most current guidelines does not necessarily lead to adequate Colistin plasma levels. Use of Colistin without therapeutic drug monitoring might be unsafe and guideline adherence does not warrant efficient target levels in critically ill patients.

show abstract

Section: High Colistin Plasma Levels Do Not Prevent Development Of Comentioning

confidence: 99%

Extensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Illumina sequencing: Due to the advances in sequencing technology available over the study period, different protocols were used to obtain short-read sequences, as described before [17,28,30]. In brief, early isolates were sequenced with 2x 50 bps on a Illumina HiSeq2000 [17], or by 2x300 bps on a Illumina Miseq [30] or using 2x250 bps on a Illumina Miseq [28]. Supplementary table 2 provides a detailed overview on the sequencing protocols applied.…”

Section: Nanopore and Illumina Sequencingmentioning

confidence: 99%

“…For visualisation Figtree version v1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/) was applied. For calculation of the Citrobacter maximum likelihood phylogeny, the 9 study isolates and 14 reference genomes were included (Citrobacter amalonaticus Y19 (CP011132_1), Citrobacter braakii GTA-CB01 (JRHK01000001.1), C. braakii GTA-CB04 (JRHL01000001.1), Citrobacter farmeri GTC 1319 (NZ_BBMX01000031.1), C. freundii CFNIH1 (NZ_CP007557_1), Citrobacter rodentium ICC168 (NC_013716_1), Citrobacter sedlakii NBRC 105722 (NZ_BBNB01000030.1), C. werkmanii NBRC 105721 (NZ_BBMW01000009.1), Citrobacter youngae ATCC 29220 (NZ_GG730308.1), Citrobacter koseri ATCC BAA-895 (CP000822.1), C. freundii ATCC 8090 (JMTA01000001.1), C. rodentium ATCC 51459 (JXUN01000001.1), C. amalonaticus L8A (JMQQ01000001.1) and C. werkmanii DSMZ17579 [30]. For P. aeruginosa, the 45 study isolates and one P. aeruginosa bla VIM outgroup strain were included in the analysis.…”

Section: Phylogenetic Analysismentioning

confidence: 99%

Tracking of antibiotic resistance transfer and rapid plasmid evolution in a hospital setting by Nanopore sequencing

Peter

Bosio

Groß

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Infection of patients with multidrug-resistant (MDR) bacteria often leave very limited or no treatment options. The transfer of antimicrobial resistance genes (ARG) carrying plasmids between bacterial species by horizontal gene transfer represents an important mode of expansion of ARGs. Here, we evaluated the application of Nanopore sequencing technology in a hospital setting for monitoring the transfer and rapid evolution of antibiotic resistance plasmids within and across multiple species.Results: In 2009 we experienced an outbreak with an extensively multidrug resistant P. aeruginosa harboring the carbapenemase enzyme bla , and in 2012 the first Citrobacter freundii and Citrobacter werkmanii harboring the same enzyme were detected. Using Nanopore and Illumina sequencing we conducted a comparative analysis of all bla

show abstract

“…Recent microbiological evidence has shown the emergence of New Delhi metallo-β-lactamase (blaNDM)producing C. werkmanii in India [10]. Another microbiological report has described the presence of MDR C. werkmanii harboring a novel blaVIM-48 resistance gene in rectal swabs [11].…”

Section: Discussionmentioning

confidence: 99%

A Case Report of Bacterial Peritonitis Caused by MBL-Producing Citrobacter werkmanii in Peritoneal Dialysis

Briano

Magnasco

Toscanini

et al. 2019

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Infections caused by Enterobacterales have become more difficult to treat due to increasing antibiotic resistance, in particular, in the case of production of carbapenemases. Bacterial peritonitis is a common complication of peritoneal dialysis, being Citrobacter spp., an uncommon cause of this syndrome. We report the first case of bacterial peritonitis in continuous ambulatory peritoneal dialysis (CAPD) caused by Citrobacter werkmanii resistant to all beta-lactams, gentamicin, and cotrimoxazole, and also the new anti-gram-negative molecules ceftazidime/avibactam and ceftolozane/tazobactam. The molecular analysis of the strain demonstrated the presence of blaVIM metallo-β-lactamase gene. The patient was effectively cured with a course of systemic tigecycline, colistin, and meropenem.

show abstract

Whole-genome sequencing enabling the detection of a colistin-resistant hypermutating Citrobacter werkmanii strain harbouring a novel metallo-β-lactamase VIM-48

Cited by 12 publications

References 38 publications

Extensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks

Extensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks

Tracking of antibiotic resistance transfer and rapid plasmid evolution in a hospital setting by Nanopore sequencing

A Case Report of Bacterial Peritonitis Caused by MBL-Producing Citrobacter werkmanii in Peritoneal Dialysis

Contact Info

Product

Resources

About